CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

The panel concluded, “Accordingly, the firm should submit the above data to CDSCO for further review by the committee.”

This FDC combines three agents frequently used in respiratory therapy:

1. Glycopyrronium bromide is an anticholinergic that reduces airway secretions by selectively blocking muscarinic receptors.

2. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) used for maintenance treatment of chronic obstructive pulmonary disease (COPD).

3. Fluticasone furoate, a corticosteroid, works by suppressing inflammatory responses involving mast cells, eosinophils, and cytokine mediators.

Glenmark now needs to submit peer-reviewed, published data to demonstrate that the systemic and therapeutic equivalence of the nebulized double dose matches that of the MDI/DPI half dose—a critical point for the requested BE waiver.

Also Read: Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma